I don't see this happening. The way the EPA market will be shaping up by 2029, we'll have Amarin, Hikma, Apotex, Teva & DR. A total of five players will not provide incentive for additional generics. If AMRN hopes to maintain its moat (assuming patent victory), it will have to redefine current formulation, discovery adjacent markets or buy out supply chain.
We're also losing time. With every passing month, the potential valuation of this firm will continue to diminish. JT and team need an execution plan NOW!